CDEK
← All drugs Report issue

permethrin

Trade name: nix

Small moleculeapproved

Approved

Mar 31, 1986

Permethrin is a synthetic pyrethrin derivative acts as a neurotoxin by depolarizing the nerve cell membrane. Permethrin disrupts the sodium channel current by which membrane repolarization is regulated resulting in fatal paralysis of the nerves in the exoskeletal respiratory muscles of susceptible arthropods, including lice and mite. Permethrin is sold under brand names NIx and Elimite to treat pediculosis, scabies and demodicidosis. — NCATS

Clinical trial activity

44 trials · 62 clinical orgs · 9 marketing orgs

Phase 1
3
Phase 2
24
Phase 3
17
Phase 4
4

Earliest trial started Jul 1, 1998 (NCT02500524)

Timeline

1980s

  1. Mar 31, 1986

    GlaxoSmithKline — Earliest FDA Approval

  2. Mar 31, 1986

    GlaxoSmithKline — NDA Organization

  3. Mar 31, 1986

    GlaxoSmithKline — NDA Secondary Org

  4. Aug 25, 1989

    Aurobindo Pharma — Marketing Organization

  5. Aug 25, 1989

    Mylan — NDA Secondary Org

  6. Aug 25, 1989

    Aurobindo Pharma — NDA Secondary Org

1990s

  1. May 2, 1990

    Medtech Products — NDA Secondary Org

  2. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

  3. Jan 23, 1998

    Actavis — Marketing Organization

2000s

  1. Dec 20, 2001

    Perrigo — Marketing Organization

  2. Apr 21, 2003

    Padagis Us — Marketing Organization

  3. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Apr 3, 2019

    Encube Ethicals Pvt. Ltd. — Marketing Organization

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Aug 1, 2023

    Dr. Reddy's Laboratories — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewMar 31, 1986

Chemistry & pharmacology

Loading structure…

SMILES

CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC2=CC(OC3=CC=CC=C3)=CC=C2
Mol. weight
391.288 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Over the Counter

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl ester
  • 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl ester
  • (3-phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
  • (3-phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
  • elimite
  • elimite
  • lyclear
  • lyclear
  • lythrin
  • nedax
  • nix
  • nix
  • nix
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permethrin
  • permetrin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07247630Early Phase 1 (Phase 1)Nov 15, 2025College of Physicians and Surgeons Pakistan, Government of Pakistan
NCT06896929Phase 2May 1, 2025Children Hospital and Institute of Child Health, Lahore
NCT06380452Phase 3May 31, 2024Infectopharm Arzneimittel GmbH, Winicker Norimed GmbH
NCT05819983Phase 4Jan 25, 2023Padjadjaran University
NCT05565820N/AOct 31, 2022Alliance Pharmaceutical Corp., South Florida Family Health and Research Centers
NCT05391230N/AJun 3, 2022Doris Duke Charitable Foundation, University of North Carolina at Chapel Hill
NCT06396507Phase 3Mar 15, 2022Damascus University, Tishreen University, University of Aleppo
NCT05643820Phase 1Mar 1, 2022Government of Pakistan
NCT05378477N/AJan 17, 2022Fudan University, Oystershell NV
NCT04814511Phase 3Jun 11, 2021Infectopharm Arzneimittel GmbH, Winicker Norimed GmbH
NCT05362513Phase 1Jun 1, 2021Government of Pakistan
NCT04332068Phase 2Nov 1, 2020Chittagong Medical College, Kenya Medical Research Institute, University of Oxford
NCT04102592N/ASep 30, 2019Conservation, Food, and Health Foundation, University of North Carolina at Chapel Hill
NCT03813069Phase 2Jan 10, 2019Government of Ethiopia, The Fred Hollows Foundation, University of London
NCT03973775Phase 3Apr 10, 2018bioRASI, LLC, Saptalis Pharmaceuticals
NCT02938975Phase 3Nov 30, 2017Ifakara Health Institute, United States Army, University of Basel
NCT03236168Phase 3Aug 1, 2017University of London
NCT03178942Phase 3Jun 1, 2017Encube Ethicals Pvt. Ltd., Novum Pharmaceutical Research Services
NCT03105505Phase 4Apr 28, 2017Barzilai Medical Center
NCT05198947N/AJan 31, 2017B.P. Koirala Institute of Health Sciences
Showing 20 of 44 trials
Page 1 / 3

Organizations

Research & Development (62)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of North Carolina at Chapel HillAcademic/Hospital4412010
Concentrics ResearchFor profit3022007
Government of PakistanGovernment3212021
ParaProFor profit3322007
Taro PharmaceuticalsFor profit3312005
University of LondonAcademic/Hospital3332016
bioRASI, LLCFor profit2212016
Infectopharm Arzneimittel GmbHFor profit2212021
Novum Pharmaceutical Research ServicesFor profit2012015
Oystershell NVFor profit2212007
South Florida Family Health and Research CentersAcademic/Hospital2112011
United States ArmyGovernment2022006
Winicker Norimed GmbHFor profit2012021
Aix-University of MarseilleAcademic/Hospital1112011
Alliance Pharmaceutical Corp.For profit1112022
Atoifi Adventist Hospital, Solomon IslandsAcademic/Hospital1012016
Barzilai Medical CenterAcademic/Hospital1112017
B.P. Koirala Institute of Health SciencesAcademic/Hospital1112017
Centers for Disease Control and Prevention (CDC)Government1012016
Children Hospital and Institute of Child Health, LahoreAcademic/Hospital1112025
62 organizations
Page 1 / 4

Marketing (14)

OrganizationOrg typeRelationshipDate
ActavisFor profitMKTGJan 23, 1998
ActavisFor profitSYNMar 28, 2000
Aurobindo PharmaFor profitMKTGAug 25, 1989
Aurobindo PharmaFor profitNDA2Aug 25, 1989
Dr. Reddy's LaboratoriesFor profitMKTGAug 1, 2023
Encube Ethicals Pvt. Ltd.For profitMKTGApr 3, 2019
GlaxoSmithKlineFor profitNDAMar 31, 1986
GlaxoSmithKlineFor profitNDA2Mar 31, 1986
Medtech ProductsFor profitNDA2May 2, 1990
MylanFor profitNDA2Aug 25, 1989
MylanFor profitSYNAug 25, 1989
Padagis UsFor profitMKTGApr 21, 2003
PerrigoFor profitMKTGDec 20, 2001
PerrigoFor profitSYNApr 21, 2003